Letter to the Editor

Rheumatology International

, Volume 29, Issue 9, pp 1113-1115

First online:

Treatment of intractable pulmonary hemorrhage in two patients with childhood systemic lupus erythematosus

  • Mohammad Hassan MoradinejadAffiliated withChildren’s Hospital Medical Center, Tehran University of Medical Sciences Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown etiology with multisystem involvement. A number of pulmonary complications including pleuritis, pneumonitis, infectious pneumonia, and pulmonary hemorrhage, have been reported in patients with SLE. Pulmonary hemorrhage is a major life-threatening manifestation in children and adolescents with SLE. Mycophenolate mofetil is an immunosuppressive agent used in solid organ transplantation, and it may play an increasing role in autoimmune disease. In this report, we present two cases of childhood SLE with recurrent pulmonary hemorrhage, which were unresponsive to treatment with high-dose corticosteroids, cytotoxic therapy, IVIG, plasmaphoresis, and supportive therapy, but responded to IV mycophenolate mofetil. A multimodal therapy including mycophenolate mofetil was effective in treatment of these two children.


Systemic lupus erythematosus Lupus pneumonitis Pulmonary hemorrhage Mycophenolate mofetil